Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 15/100

Failure Rate

0.0%

0 terminated/withdrawn out of 21 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

57%

12 trials in Phase 3/4

Results Transparency

50%

10 of 20 completed trials have results

Key Signals

1 recruiting10 with results

Enrollment Performance

Analytics

Phase 3

11(52.4%)

Phase 2

7(33.3%)

Phase 1

2(9.5%)

Phase 4

1(4.8%)

21Total

Phase 3(11)

Phase 2(7)

Phase 1(2)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (21)

Showing 20 of 21 trials

NCT06765668Phase 4Recruiting

A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease

Role: lead

NCT00617695Phase 3Completed

Efficacy of Zolmitriptan (Zomig) in the Treatment of Migraines in Adolescents

Role: lead

NCT06161220Phase 1Completed

A TQT Study to Evaluate the Electrocardiographic Effects of Carbidopa in Healthy Subjects

Role: lead

NCT03877510Phase 3Completed

Open Label Extension (OLE) Study of the Safety and Clinical Utility of IPX203 in Parkinson's Disease (PD) Participants With Motor Fluctuations

Role: lead

NCT03670953Phase 3Completed

A Study to Evaluate the Safety and Efficacy of IPX203 in Parkinson's Disease Participants With Motor Fluctuations

Role: lead

NCT03007888Phase 2Completed

A Study to Assess the PK and Pharmacodynamics of IPX203 in Subjects With Advanced Parkinson's Disease

Role: lead

NCT02770365Phase 3Completed

Comparative Safety and Efficacy of Two Treatments in the Treatment of Vulvar and Vaginal Atrophy

Role: collaborator

NCT03275922Phase 3Completed

Efficacy & Safety Of Zomig Nasal Spray For Acute Migraine Treatment In Subjects 6 To 11 Years, With OLE

Role: lead

NCT00974974Phase 3Completed

A Study To Evaluate The Safety And Efficacy Of IPX066 In Advanced Parkinson's Disease (ADVANCE-PD).

Role: lead

NCT00869791Phase 2Completed

A Study to Compare Pharmacokinetics and Pharmacodynamics of IPX066 to Standard Carbidopa-Levodopa

Role: lead

NCT01096186Phase 3Completed

An Open Label Extension Study of the Safety and Clinical Utility of IPX066 in Subjects With Parkinson's Disease

Role: lead

NCT01411137Phase 3Completed

Carbidopa-Levodopa (CD-LD) ER Alone or in Combination With CD-LD IR to IPX066 Followed by IPX066 Extension Safety Study

Role: lead

NCT02271503Phase 2Completed

A Study to Assess the PK and Pharmacodynamics of IPX203 in Patients With Advanced Parkinson's Disease

Role: lead

NCT00488839Phase 3Completed

IPX056 in Subjects With Established Spasticity Resulting From Multiple Sclerosis

Role: lead

NCT00914290Phase 2Completed

A Study With IPX056 in Subjects With Spasticity Associated With Multiple Sclerosis

Role: lead

NCT00253084Phase 2Completed

Comparison of IPX054 and Immediate-Release Carbidopa-Levodopa in Patients With Parkinson's Disease

Role: lead

NCT00880620Phase 3Completed

A Study To Evaluate The Safety And Efficacy Of IPX066 In Subjects With Parkinson's Disease

Role: lead

NCT00239564Phase 1Completed

Pharmacokinetics and Pharmacodynamics of IPX054 in Subjects With Parkinson's Disease

Role: lead

NCT00279825Phase 2Completed

Comparison of IPX054, IR Carbidopa-Levodopa, and CR Carbidopa-Levodopa in Subjects With Parkinson's Disease

Role: lead

NCT01130493Phase 3Completed

A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066

Role: lead